NICE technology appraisals of oncology treatments
The appraisal of oncology treatments is a key activity conducted by the National Institute for Health and Care Excellence (NICE). As part of the Department of Health and Social Care in England, NICE provides evidence-based best practices to help get the best care to patients while ensuring value for the taxpayer.
The assessments and recommendations made by NICE have a profound impact on the accessibility of cancer treatments in England and Wales and often serve as a reference point for health technology assessment (HTA) bodies worldwide.
To help manufacturers (drug development sponsors) incorporate market access planning and navigate the complex landscape of HTA evaluation of innovative oncology treatments, Fortrea Market Access Consulting & HEOR has published a white paper that covers:
- An overview of NICE assessment methods
- Health economic modeling approaches
- The impact of NICE’s new severity modifier
- Implications for manufacturers
Through a review of 66 technology appraisals over two years, the authors highlight an important challenge faced by manufacturers with an oncology portfolio and discuss the need for careful market access planning to inform reimbursement and pricing strategies.
For more on Fortrea's extensive experience and expertise in Oncology therapeutic development, visit https://www.fortrea.com/scientific-expertise/by-therapeutic-or-specialty-areas/oncology.html
